Community-acquired lung respiratory infections in HIV-infected patients: Microbial aetiology and outcome

European Respiratory Journal

Volumn 43, Issue 6, 2014, Pages 1698-1708

  Cilloniz, Catia ^a,b   Torres, Antoni ^a,b   Polverino, Eva ^a,b   Gabarrus, Albert ^a,b   Amaro, Rosanel ^a,b   Moreno, Encarnacion ^a,b   Villegas, Santiago ^c   Ortega, Mar ^d   Mensa, Josep ^d   Marcos, Maria Angeles ^e   Asuncion, Moreno ^d   Miro, Jose M ^d  

^a HOSPITAL CLÍNIC   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c UNIVERSIDAD CES   (Colombia)

^d UNIVERSITY OF BARCELONA   (Spain)

^e CENTRE FOR RESEARCH IN ENVIRONMENTAL EPIDEMIOLOGY CREAL   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; LACTATE DEHYDROGENASE; ANTIINFECTIVE AGENT;

ADULT; ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC THERAPY; ARTICLE; ARTIFICIAL VENTILATION; BACTERIUM DETECTION; CD4 LYMPHOCYTE COUNT; COMMUNITY ACQUIRED INFECTION; COMMUNITY ACQUIRED PNEUMONIA; DISEASE ASSOCIATION; FEMALE; HEPATITIS C VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOSPITALIZATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; LENGTH OF STAY; LEUKOCYTE COUNT; LOW RISK PATIENT; LUNG INFILTRATE; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; MORTALITY; OBSERVATIONAL STUDY; PNEUMOCYSTIS JIROVECI; PREDICTOR VARIABLE; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; RESPIRATORY TRACT INFECTION; RISK FACTOR; SPAIN; STREPTOCOCCUS PNEUMONIAE; VIRUS LOAD; CHEMISTRY; COMPLICATION; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LUNG DISEASE; MICROBIOLOGY; MIDDLE AGED; TIME; TREATMENT OUTCOME;

ADULT; ANTI-BACTERIAL AGENTS; CD4 LYMPHOCYTE COUNT; COMMUNITY-ACQUIRED INFECTIONS; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; LUNG DISEASES; MALE; MIDDLE AGED; PNEUMOCYSTIS JIROVECII; PROGNOSIS; PROSPECTIVE STUDIES; RISK FACTORS; STREPTOCOCCUS PNEUMONIAE; TIME FACTORS; TREATMENT OUTCOME;

EID: 84901845839     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00155813     Document Type: Article

References (16)

1. Feikin DR, Feldman C, Schuchat A, et al. Global strategies to prevent bacterial pneumonia in adults with HIV disease. Lancet Infect Dis 2004; 4: 445-455. (Pubitemid 38844129)
2. Benito N, Moreno A, Miro JM, et al. Pulmonary infections in HIV-infected patients: an update in the 21st century. Eur Respir J 2012; 39: 730-745.
3. Madeddu G, Porqueddu EM, Cambosu F, et al. Bacterial community acquired pneumonia in HIV-infected inpatients in the highly active antiretroviral therapy era. Infection 2008; 36: 231-236.
4. Hirschtick R, Glassroth J, Jordan M, et al. Bacterial pneumonia in persons infected with the human immunodeficiency virus. N Engl J Med 1995; 333: 845-851.
5. Phair J, Munoz A, Detels R, et al. The risk of Pneumocystis carinii pneumonia among men infected with human immunodeficiency virus type 1. Multicenter Aids Cohort Study Group. N Engl J Med 1990; 322: 161-165. (Pubitemid 20036389)
6. Llibre JM, Revollo B, Vanegas S, et al. Pneumocystis jirovecii pneumonia in HIV-1-infected patients in the late-HAART era in developed countries. Scand J Infect Dis 2013; 45: 635-644.
7. Napoli AM, Maughan B, Murray R, et al. Use of the relationship between absolute lymphocyte count and cd4 count to improve earlier consideration of Pneumocystis pneumonia in HIV-positive emergency department patients with pneumonia. J Emerg Med 2013; 44: 28-35.
8. Antinori A, Coenen T, Costagiola D, et al. Late presentation of HIV infection: a consensus definition. HIV Med 2011; 12: 61-64.
9. Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society Of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007; 44: Suppl. 2, S27-S72. (Pubitemid 46290553)
10. Hosmer D, Lemeshow S. Applied Logistic Regression, New York, Wiley, 1989.
11. Cordero E, Pachon J, Rivero A, et al. Community-acquired bacterial pneumonia in human immunodeficiency virus-infected patients: validation of severity criteria. The Grupo Andaluz Para El Estudio De Las Enfermedades Infecciosas. Am J Respir Crit Care Med 2000; 162: 2063-2068. (Pubitemid 32051665)
12. Sogaard OS, Reekie J, Ristola M, et al. Severe bacterial non-AIDS infections in HIV-positive persons: incidence rates and risk factors. J Infect 2013; 66: 439-446.
13. Vogel M, Weissgerber P, Goeppert B, et al. Accuracy of serum LDH elevation for the diagnosis of Pneumocystis jiroveci pneumonia. Swiss Med Wkly 2011; 141: W13184.
14. Gordin FM, Roediger MP, Girard PM, et al. Pneumonia in HIV-infected persons: increased risk with cigarette smoking and treatment interruption. Am J Respir Crit Care Med 2008; 178: 630-636.
15. Shivji M, Burger S, Moncada CA, et al. Effect of nicotine on lung S-adenosylmethionine and development of Pneumocystis pneumonia. J Biol Chem 2005; 280: 15219-15228. (Pubitemid 40562878)
16. Varez-Martinez MJ, Moreno A, Miro JM, et al. Pneumocystis jirovecii pneumonia in Spanish HIV-infected patients in the combined antiretroviral therapy era: prevalence of dihydropteroate synthase mutations and prognostic factors of mortality. Diagn Microbiol Infect Dis 2008; 62: 34-43.